Interim Order
187 interim order decisions from Delhi High Court - Orders.
Interim Order Decisions
187 cases | Page 7 of 7
Pfizer Inc. v.Everest Pharmaceuticals Ltd.
Pfizer Inc. filed a suit seeking permanent injunction against Everest Pharmaceuticals Ltd. for infringement of Indian Patents Nos. 241773 and 218212, which cover Tofacitinib (XELJANZ(R)). The plaintiffs alleged that defendants were illegally manufacturing and selling generic versions under the brand 'TOFAXEN'.
Merck Sharp & Dohme Corp. v.Achemic Pharmaceuticals (India) Pvt. Ltd.
The plaintiffs, holding patents and licenses for Sitagliptin (under trade names ISTAVEL and ISTAMET), filed a suit alleging that the defendant was manufacturing and selling the drug under the brand name TwoTrack, thereby infringing their patent. The court found that the plaintiffs had made out a prima facie case and granted an ex parte ad interim injunction.
Merck Sharp & Dohme Corp. v.Triveni Interchem Private Limited
The plaintiff, Merck Sharp & Dohme Corp., filed a suit alleging that the defendant, Triveni Interchem Private Limited, was selling and advertising various compositions of Sitagliptin without taking any license. The plaintiff holds a valid patent for Sitagliptin.
All India Patent Officers Welfare Association v.Union Of India & Ors
The All India Patent Officers Welfare Association filed a petition alleging that the Controller General of Patents, Designs and Trademarks (CGPDTM) unlawfully provided access to sensitive, unpublished trademark and patent application data to a private multinational company. The petitioner argued this access lacked necessary checks and balances. The Delhi High Court accepted the petition and directed an investigation into the matter, setting a timeline for the respondents to file their reply.
Novartis Ag v.Natco Pharma Limited
The plaintiffs filed an application seeking to defer or modify the appointment of a scientific expert to determine if the defendant's product, VALSAC, falls within the scope of Claim 1 of their patent (IN 229051). The court accepted the suggestion to appoint an expert from the Roll of Experts and framed a specific question for the appointed Expert Advisor.
Novartis Ag v.Natco Pharma Limited
Novartis filed a suit seeking permanent injunction against Natco Pharma Limited for infringing its patented pharmaceutical composition, Valsartan + Sacubitril (Patent No. 229051). The dispute centered on whether Natco's product, VALSAC, was identical to the claimed invention. The court found prima facie merit in Novartis' contentions and appointed an independent Expert Advisor to determine infringement.
Biogen International Gmbh v.Jayesh Shah
The court passed an order disposing of several applications filed by both parties. The existing interim injunction was confirmed, and the defendant was permitted to sell their existing stock of 'DYFIRA' under specific conditions. This permission required the defendant to furnish a bank guarantee of Rs.30 lacs to secure potential damages.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.